Relmada Therapeutics, Inc. (RLMD)

Market Cap	13.22M
Revenue (ttm)	n/a
Net Income (ttm)	-79.98M
Shares Out	33.19M
EPS (ttm)	-2.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	763,799
Open	0.4400
Previous Close	0.4195
Day's Range	0.3842 - 0.4500
52-Week Range	0.2400 - 4.4700
Beta	0.18
Analysts	Hold
Price Target	4.25 (+967.04%)
Earnings Date	May 12, 2025

About RLMD

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 17
• Stock Exchange: NASDAQ
• Ticker Symbol: RLMD
• Website: https://www.relmada.com

Analyst Forecast

According to 4 analysts, the average rating for RLMD stock is "Hold." The 12-month stock price forecast is $4.25, which is an increase of 967.04% from the latest price.

Price Target

$4.25

(967.04% upside)

Analyst Consensus: Hold